Friday January 18, 2019

Minimum Death Risk For Breast Cancer Patients From Heart Ailments

The scientists found that the long-term risk of mortality from heart disease is not higher following breast cancer treatment than in the average female population

0
//
Pink Ribbon Campaign
Breast Cancer. Pixabay

Contrary to earlier findings, German researchers have concluded that there is no higher risk of death from heart disease in breast cancer patients following radiotherapy or chemotherapy.

In a largest cohort study evaluating data from almost 350,000 patients from the US cancer registries, the team found that the risk is no higher than it is among the average population. Good risk management in the hospitals, as well as control screenings at short intervals, seem to make up for elevated risks, said researchers from the German Cancer Research Centre (DKFZ) in Heidelberg.

Risk of death from heart ailments is less in women suffering from Breast Cancer.

“At first, we were also surprised by this result. But we assume that our study paints a more realistic picture of the actual situation of treatment than clinical trials,” said Janick Weberpals, the study’s initial author, in a paper published in the European Heart Journal.

Breast cancer is the second-most frequent cancer worldwide and the most common cancer in women. However, improved screening measures and more effective treatment methods have considerably lowered the risk of succumbing to the disease.

Also Read: Breastfeeding May Reduce Hypertension Risk

“However, a number of clinical trials have suggested that both chemotherapy and radiotherapy are associated with the risk of suffering heart disease as a consequence of treatment,” said Hermann Brenner from DKFZ.

Brenner’s team analysed cases of women who were diagnosed with breast cancer in the years 2000-2011 and subsequently received treatment by radiotherapy or chemotherapy. The scientists found that the long-term risk of mortality from heart disease is not higher following breast cancer treatment than in the average female population.

Breast cancer awareness is very important in India.

“We consider the result of our study to be very positive for the treatment of breast cancer,” said Brenner. “It is particularly good news for the large number of affected patients that if they are in good medical care and have survived breast cancer, they do not need to be more worried about deadly heart diseases than women at the same age without breast cancer,” the researchers added. IANS

Next Story

Drugs of Breast Cancer Useful in Treating Drug-Resistant Lung Tumours

For the study, the researchers targeted a specific interaction between the RAS protein and p110a

0
cancer
What is to be blamed for childhood cancer? Find it out here. Pixabay

A class of drugs used to treat certain breast cancer could help tackle lung cancers that have become resistant to targeted therapies, suggests a study done on mice.

The study showed that lung tumours in mice caused by mutations in a gene called EGFR shrunk significantly when a protein called p110a was blocked by the drugs.

“At the moment, patients with EGFR-mutant lung cancers are given targeted treatments that are very effective for the first few years,” said lead researcher Julian Downward, Associate Research Director of the Francis Crick Institute in the UK.

“These drugs are improving, but unfortunately after a couple of years, cancer usually becomes resistant and starts to grow and spread again. The second line of treatment is currently conventional chemotherapy, which is not targeted and has substantial side-effects,” said Downward.

Importantly, it would be worth investigating whether p110a inhibitors could be used as second-line therapy.

Cancer
Cancer Ribbon. Pixabay

Findings, published in Cell Reports, showed that when they blocked this interaction in genetically modified mice with EGFR mutations, their tumours shrank significantly to about a tenth of the space inside the lung.

Before the intervention, the tumours filled around two-thirds of the space inside the lung.

Also Read- Earthquake Measuring 6.1 Strikes Indonesia

These drugs could potentially benefit patients with EGFR-mutant lung cancers whose tumours have become resistant to treatment and could be approved for clinical purposes in the near future, the team suggested.

Since the research is at such an early stage, more research in mice and patient cells would be needed, Downward noted. (IANS)